TREATMENT OUTCOME IN HODGKINS-DISEASE IN PATIENTS ABOVE THE AGE OF 60 - A POPULATION-BASED STUDY

被引:65
作者
ENBLAD, G [1 ]
GLIMELIUS, B [1 ]
SUNDSTROM, C [1 ]
机构
[1] UNIV UPPSALA, AKAD SJUKHUSET, DEPT PATHOL, S-75185 UPPSALA, SWEDEN
关键词
AGE; HODGKINS DISEASE; PROGNOSIS;
D O I
10.1093/oxfordjournals.annonc.a057939
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
All persons in three Swedish counties afflicted with Hodgkin's disease between 1979 and 1988 were traced. The objective was to analyze, in unselected, population-based material, whether an assumed worse prognosis in the elderly could be due to differences in staging procedures, treatment intensity, decreased tolerance to therapy or to a more aggressive disease. After histopathological revision, 163 of 202 patients (autopsy cases excluded) were accepted as HD, 61 (37%) of them above the age of 60. Although staging procedures had been more intense in the young, the elderly patients had a more advanced stage at diagnosis, and tended more often to have B-symptoms. The intensity of staging procedures did not seem to influence survival. The 5-yr relative survival was 37% above and 85% below the age of 60. Radiotherapy was the primary treatment in 12 (20%) above and 41 (41%) below the age of 60 with 5-yr relative survival figures of 84% and 85%, respectively. Thirty-seven patients (61%) above and 61 (59%) below 60 were treated with combination chemotherapy (MOPP/ABVD, MOPP, ChlVPP/OPEC) with curative intent. The 5-yr relative survival was 33% and 86%, respectively. The majority of the elderly patients (54%) received less than 40% of the planned chemotherapy dose. The main reason for this pronounced reduction was intolerance to therapy, with 8 treatment-related deaths. We conclude that tolerance to combination chemotherapy in the elderly patients with HD is poor and could be the major reason for poor treatment outcome in this age group.
引用
收藏
页码:297 / 302
页数:6
相关论文
共 30 条
[1]   HODGKINS-DISEASE IN PATIENTS OVER 60 YEARS OLD [J].
AUSTINSEYMOUR, MM ;
HOPPE, RT ;
COX, RS ;
ROSENBERG, SA ;
KAPLAN, HS .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (01) :13-18
[2]  
BENNETT MH, CLIN RAD, P491
[3]  
BONADONNA G, 1982, CANCER TREAT REP, V66, P881
[4]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[5]  
CUTLER SJ, 1958, J CHRON DIS, V8, P699
[6]   5 YEARS EXPERIENCE WITH CHLVPP - EFFECTIVE LOW-TOXICITY COMBINATION CHEMOTHERAPY FOR HODGKINS-DISEASE [J].
DADY, PJ ;
MCELWAIN, TJ ;
AUSTIN, DE ;
BARRETT, A ;
PECKHAM, MJ .
BRITISH JOURNAL OF CANCER, 1982, 45 (06) :851-859
[7]  
DeVita V. T., 1967, P AM ASSOC CANC RES, V8, P13
[8]  
DEVITA VT, 1989, CANCER PRINCIPLES PR
[9]  
EGHBALI H, 1984, CANCER, V53, P2191, DOI 10.1002/1097-0142(19840515)53:10<2191::AID-CNCR2820531031>3.0.CO
[10]  
2-0